Y-mAbs Therapeutics, Inc.

NasdaqGS:YMAB Rapport sur les actions

Capitalisation boursière : US$556.7m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Y-mAbs Therapeutics Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Mike Rossi

Directeur général

US$3.1m

Rémunération totale

Pourcentage du salaire du PDG3.5%
Durée du mandat du directeur généralless than a year
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction3.4yrs
Durée moyenne du mandat des membres du conseil d'administration6.7yrs

Mises à jour récentes de la gestion

Recent updates

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Aug 12

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Jul 15
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Jun 02
Investors Don't See Light At End Of Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Tunnel And Push Stock Down 29%

Y-mAbs: There's A Ceiling Here Somewhere

May 09

We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Mar 14
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Feb 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares Bounce 66% But Its Business Still Trails The Industry

Y-mAbs Therapeutics: A Monoclonal Antibody Play

Jan 14

We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

Nov 13
We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Jul 16
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth

Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

May 13
Party Time: Brokers Just Made Major Increases To Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Earnings Forecasts

Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Apr 17
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Price Is Right But Growth Is Lacking After Shares Rocket 104%

Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

Mar 22
Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Dec 13
We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Needs To Drive Business Growth Carefully

Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Aug 13
Analysts Just Shaved Their Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Forecasts Dramatically

Y-mAbs gets FDA nod to begin phase 1 study of GD2-SADA for certain cancers

Jul 12

Y-mAbs Therapeutics: Steady, Small Steps Targeting Rare Cancers

May 30

Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

May 12
Is Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?

Analyse de la rémunération des PDG

Comment la rémunération de Mike Rossi a-t-elle évolué par rapport aux bénéfices de Y-mAbs Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$25m

Mar 31 2024n/an/a

-US$22m

Dec 31 2023US$3mUS$110k

-US$21m

Rémunération vs marché: La rémunération totale de Mike ($USD 3.11M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 2.44M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Mike avec les performances de l'entreprise.


PDG

Mike Rossi (53 yo)

less than a year

Titularisation

US$3,110,553

Compensation

Mr. Michael Rossi, also known as Mike, serves as Chief Executive Officer, President & Director of Y-mAbs Therapeutics, Inc. since November 06, 2023. He has been Director at Nucleus RadioPharma, Inc. He had...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Michael Rossi
CEO, President & Directorless than a yearUS$3.11mpas de données
Thomas Gad
Founder9.3yrsUS$2.45m0.75%
$ 4.2m
Susan Smith
Senior VP & Chief Commercial Officer2.6yrsUS$887.28k0.0095%
$ 53.1k
Peter Pfreundschuh
CFO & Treasurerless than a yearpas de donnéespas de données
Joris Wiel Wilms
Senior VP & COO6.8yrspas de données0.013%
$ 74.1k
Torben Lund-Hansen
Senior VP & CTO8.6yrspas de données0.12%
$ 644.4k
Courtney Dugan
Vice President of Investor Relationsno datapas de donnéespas de données
Vignesh Rajah
Senior VP & Chief Medical Officer4.2yrsUS$724.92k0.019%
$ 106.0k
Norman D. LaFrance
Chief Development Officerless than a yearpas de donnéespas de données

3.4yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de YMAB est considérée comme expérimentée (ancienneté moyenne 3.4 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Michael Rossi
CEO, President & Directorless than a yearUS$3.11mpas de données
Thomas Gad
Founder9.3yrsUS$2.45m0.75%
$ 4.2m
James Healy
Independent Chairman of the Board6.8yrsUS$184.31k0.063%
$ 351.1k
David Gill
Independent Director6.7yrsUS$180.56k0.0052%
$ 29.1k
Mary Tagliaferri
Directorless than a yearpas de données0%
$ 0
Johan Wedell-Wedellsborg
Independent Director8.9yrsUS$158.06k0.0052%
$ 29.1k
Ashutosh Tyagi
Independent Director6.8yrsUS$158.06k0.0052%
$ 29.1k
Laura Hamill
Independent Director4.2yrsUS$168.06k0.0052%
$ 29.1k

6.7yrs

Durée moyenne de l'emploi

56yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de YMAB sont considérés comme expérimentés (ancienneté moyenne 6.7 ans).